Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
J Paediatr Child Health ; 58(10): 1829-1835, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35822947

RESUMEN

AIM: Children with sickle cell disease (SCD) have historically weighed less than their healthy peers. More recently, a retrospective chart review from six institutions in New England reported nearly one-quarter of children and adolescents with SCD had raised body mass index (BMI). This study aimed to examine rates of children with SCD with raised BMI in Mississippi compared to state and national norms and assess the correlation between haemoglobin and BMI. METHODS: A retrospective chart review of paediatric patients with SCD at the University of Mississippi Medical Center (UMMC) was conducted using data from the most recent clinic visit. Mississippi and national weight status estimates for youth 10-17 years were obtained from the 2016-2017 National Survey of Children's Health. RESULTS: For youth 10-17 years with SCD (n = 345), 21.4.% of children with SS/Sß° and 36.1% with SC/Sß+ had raised BMI compared to Mississippi and national rates, 39.2 and 31%, respectively. The prevalence of children with raised BMI with SC/Sß+ did not differ from state and national rates, while children with SS/Sß° were half as likely as their Mississippi peers to have raised BMI. Haemoglobin levels were different among children with SCD who had low BMI (8.80 g/dL), average BMI (9.2 g/dL) and raised BMI (10.5 g/dL) (P < 0.001). CONCLUSIONS: Children with SCD evaluated at UMMC have similar rates of raised BMI compared to state and national norms. Children with raised BMI have higher mean haemoglobin levels compared to children with SCD with low or average BMI. IMPLICATIONS AND CONTRIBUTION: Historically, patients with SCD have been underweight and normal weight. Our paediatric and adolescent patients with SCD now have prevalence rates of raised BMI that approach state and national rates. Further work must be done to determine whether this reflects healthier children with SCD or raises concerns about life-style-related comorbidities.


Asunto(s)
Anemia de Células Falciformes , Adolescente , Anemia de Células Falciformes/epidemiología , Índice de Masa Corporal , Niño , Hemoglobinas , Humanos , Prevalencia , Estudios Retrospectivos
2.
Cutis ; 106(2): 87-92, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32941554

RESUMEN

Lasers are being used in ever-expanding roles in dermatology. As our understanding of laser energy grew, the need for safety guidelines became apparent. The US Food and Drug Administration (FDA) published the first safety guidelines in 1984, which are updated on a regular basis. However, these are just guidelines, and their implementation is voluntary by the laser practitioner. In this article, we discuss the 4 regulatory entities for laser safety in the United States, laser principles in general, ocular hazards, laser-generated airborne contaminants (LGACs), fires, and unintended laser beam injuries. We also review the use of checklists in reducing adverse outcomes and the need for safety protocols for laser practitioners. We provide a modifiable checklist, which pertains specifically to lasers and can be customized to meet the needs of the individual laser practitioner.


Asunto(s)
Terapia por Láser/métodos , Rayos Láser/normas , Guías de Práctica Clínica como Asunto , Lista de Verificación , Dermatología/legislación & jurisprudencia , Dermatología/métodos , Seguridad de Equipos , Humanos , Terapia por Láser/efectos adversos , Rayos Láser/efectos adversos , Estados Unidos , United States Food and Drug Administration
3.
Am J Clin Dermatol ; 20(5): 691-698, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31111408

RESUMEN

Onychomycosis is a common disorder that is difficult to cure. Prevalence is lower in children (0.7%), but athletes are 2.5-fold more likely to develop the disease, with infections of the toenails seven times more prevalent than those of the fingernails. This is a concern for athletes as it can interfere with their performance. The risk of developing onychomycosis is increased by the warm environment of many sports activities; the use of occlusive footwear; the warm, moist environment associated with socks and sweating; shared, close quarters among athletes; and trauma to the foot and toenail. Once infected, onychomycosis treatment requires a long duration of treatment with strict compliance, a potential problem for younger patients. Treatment carries the risk of significant side effects, and recurrence rates remain high. Avoiding infection can be a potent first line of defense and may circumvent the need for treatment. Preventive recommendations such as keeping toenails short and proper washing of laundry, to name a few, can be effective and are discussed here. Technological improvements such as synthetic, moisture-wicking socks and well-ventilated, mesh shoes have also been shown to reduce moisture and injury. Education about preventing fungal spread and improving hygiene in the locker room, gym, and pool are of critical importance. This overview of onychomycosis focuses primarily on the preventive measures and innovative changes in athletic gear. It also provides a compact step-by-step guide to prevention intended to be useful for both the general public and the professional. It can be reproduced to use as a handout for athletes, trainers, and coaches.


Asunto(s)
Atletas , Dermatosis del Pie/prevención & control , Onicomicosis/prevención & control , Zapatos/efectos adversos , Dermatosis del Pie/epidemiología , Dermatosis del Pie/etiología , Humanos , Higiene , Onicomicosis/epidemiología , Onicomicosis/etiología , Educación del Paciente como Asunto , Prevalencia , Factores de Riesgo
4.
J Miss State Med Assoc ; 57(12): 382-385, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30398806

RESUMEN

A Mississippi perspective on arsenic poisoning is largely related to thousands of asthma patients cared for by one physician, Elmer D. Gay, MD, in the 1950s. The general medical uses of arsenic and its specific use in intractable asthma are reviewed along with the dermatologic manifestations of arsenic poisoning.


Asunto(s)
Intoxicación por Arsénico/diagnóstico , Enfermedades de la Piel/inducido químicamente , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA